Electrodiagnosis

Assure Holdings to Acquire Sentry Neuromonitoring

Thursday, February 25, 2021 - 1:30pm

DENVER, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that effective February 24, 2021, it has signed a Term Sheet (Term Sheet) to acquire (the Acquisition) Sentry Neuromonitoring, LLC (Sentry), one of the largest IONM service providers in Texas, for a purchase price of $3,500,000.

Key Points: 
  • DENVER, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that effective February 24, 2021, it has signed a Term Sheet (Term Sheet) to acquire (the Acquisition) Sentry Neuromonitoring, LLC (Sentry), one of the largest IONM service providers in Texas, for a purchase price of $3,500,000.
  • Under the Term Sheet, Assure will acquire Sentrys contracts, employees, business relationships and assets including accounts receivable, and assume up to $250,000 of its debt.
  • In 2020, Sentry performed more than 5,500 IONM procedures and approximately 50% ofthese procedures were commercial insurance payors.
  • Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries.

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Tuesday, February 23, 2021 - 6:33pm

The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.

Key Points: 
  • The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.
  • The study demonstrated that low-cost mEEG devices both conveniently and accurately measure EEG and human-event related brain potentials (ERPs) that can predict cognitive states like fatigue.
  • "Our work clearly demonstrates that mobile EEG systems can be used to quickly assess the brain state of people in any environment," says Krigolson.
  • "These results suggest a capacity to use mobile EEG technology for brain performance assessments in industry, healthcare, and personal use settings."

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Tuesday, February 23, 2021 - 6:16pm

The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.

Key Points: 
  • The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.
  • The study demonstrated that low-cost mEEG devices both conveniently and accurately measure EEG and human-event related brain potentials (ERPs) that can predict cognitive states like fatigue.
  • "Our work clearly demonstrates that mobile EEG systems can be used to quickly assess the brain state of people in any environment," says Krigolson.
  • "These results suggest a capacity to use mobile EEG technology for brain performance assessments in industry, healthcare, and personal use settings."

Rhythmlink Receives FDA Clearance for New MR Conditional Electrode Line

Tuesday, February 23, 2021 - 1:00pm

Rhythmlink International, LLC has announced FDA clearance of a new product line.

Key Points: 
  • Rhythmlink International, LLC has announced FDA clearance of a new product line.
  • Sticky Pad Surface Electrodes, a line of peel and stick-on electrodes for Intraoperative Neurophysiological Monitoring (IONM) and Electroencephalography (EEG) are now FDA Cleared MR Conditional for 1.5 and 3 Tesla MRI environments.
  • View the full release here: https://www.businesswire.com/news/home/20210223005148/en/
    MR Conditional Sticky Pads are specially designed for stimulating, recording or grounding.
  • Rhythmlinks original Sticky Pad Electrode line set a new industry benchmark as the only Sticky Pad Electrode to be cleared for both recording and stimulating.

Assure to Attend Upcoming Investor Conferences

Friday, February 12, 2021 - 1:30pm

DENVER, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announces that management will participate in the following investor conferences:

Key Points: 
  • DENVER, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announces that management will participate in the following investor conferences:
    MicroCap Rodeo Winter Wonderland Conference February 16-19, 2021.
  • Assure management will be meeting with investors at the conference.
  • Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commissions Gold Seal of Approval.
  • Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

B-Secur Receives FDA Regulatory Clearance For Its HeartKey® EKG/ECG Technology

Thursday, February 4, 2021 - 5:00pm

B-Secur , a leader in EKG/ECG technology, today announced that it has received U.S. Food and Drug Administration (FDA) 510(K) clearance of its HeartKey software library1.

Key Points: 
  • B-Secur , a leader in EKG/ECG technology, today announced that it has received U.S. Food and Drug Administration (FDA) 510(K) clearance of its HeartKey software library1.
  • This clearance should significantly aid our partners and customers increase the speed to market for their technology.
  • FDA clearance has been granted for the following EKG/ECG feature algorithms: Signal Conditioning, Heart Rate and Arrhythmia Analysis.
  • FDA clearance of the HeartKey software library ensures B-Secur customers and partners can have confidence in its world-leading algorithm performance and accuracy.

New Wearable ECG Recorder Gets FDA Clearance: Versatile Wearable Sensor offers Extended Ambulatory ECG Recording Up to 21 Days

Wednesday, February 3, 2021 - 2:00pm

MANLIUS, N.Y., Feb. 3, 2021 /PRNewswire-PRWeb/ -- Global Instrumentation, LLC, announced today the FDA has cleared the company's ultra-small wearable electrocardiogram (ECG) sensor, the M5 Recorder.

Key Points: 
  • MANLIUS, N.Y., Feb. 3, 2021 /PRNewswire-PRWeb/ -- Global Instrumentation, LLC, announced today the FDA has cleared the company's ultra-small wearable electrocardiogram (ECG) sensor, the M5 Recorder.
  • The device offers research organizations and physicians a reliable, shower-proof, and patient-friendly ECG sensor for precise long-term ECG data collection in the patient's home and ambulatory environments.
  • The M5 Recorder is water-resistant and weighs only 26 grams yet can store up to 21 days of 3-channel ECG recordings.
  • Through our proven research, design, and innovation capabilities, we partner closely with our customers to help enable the delivery of better healthcare.

Assure Holdings Adds New Surgeons to its Platform in Arizona

Monday, February 1, 2021 - 10:30pm

DENVER, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), has added new surgeons to itsplatform in Arizona (the Agreement).

Key Points: 
  • DENVER, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), has added new surgeons to itsplatform in Arizona (the Agreement).
  • Pursuant to the Agreement, Assure is providing IONM for four hospitals serving residents in the Phoenix metro area.
  • Phoenix is an important emerging market for Assure as we extend our brand awareness in Arizona.
  • The Arizona surgeons added to Assures platform perform approximately 1,000 orthopedic spine cases per year.

Cardiac Insight Comments on Medicare Administrative Contractor Novitas Rate Publication

Monday, February 1, 2021 - 8:46pm

Cardiac Insight , Inc. a healthcare innovator specializing in wearable cardiac sensors and proven automated electrocardiogram (ECG) analysis that delivers highly differentiated benefits to healthcare providers and patients, commented on the recent reimbursement rates published by Medicare Administrative Contractor (MAC) Novitas Solutions (Novitas) for CPT codes 93241, 93243, 93245, and 93247.

Key Points: 
  • Cardiac Insight , Inc. a healthcare innovator specializing in wearable cardiac sensors and proven automated electrocardiogram (ECG) analysis that delivers highly differentiated benefits to healthcare providers and patients, commented on the recent reimbursement rates published by Medicare Administrative Contractor (MAC) Novitas Solutions (Novitas) for CPT codes 93241, 93243, 93245, and 93247.
  • Novitas provides administrative and claims processing services for state and federal health care programs such as Medicare and Medicaid and is owned by GuideWell.
  • This untenable decision significantly sets back patient care as it will limit access to extended ECG testing for patients and physicians nationwide, said Brad Harlow, CEO of Cardiac Insight.
  • ABOUT CARDIAC INSIGHT, INC: Cardiac Insight, Inc. ( www.cardiacinsightinc.com ) is a leading U.S. digital healthcare innovation company specializing in the development of medical-grade, body-worn ECG sensor technology and automated cardiac analysis solutions through its proprietary algorithms and software platforms.

Worldwide Wireless ECG Devices Industry to 2025 - Declining Cost of Wireless Technologies is Driving Growth - ResearchAndMarkets.com

Monday, February 1, 2021 - 5:35pm

Of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.

Key Points: 
  • Of these deaths, an estimated 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.
  • Increasing awareness regarding early detection and management of cardiovascular diseases is augmenting the demand for continuous cardiovascular ECG monitoring devices.
  • The development of commercially advanced devices, with enabled Bluetooth sensor technology and mobile app technology, is anticipated to drive the popularity of continuous cardiovascular ECG monitoring systems.
  • The United States holds the largest market share in the North American wireless ECG devices market, and it is expected to register a high growth rate over the forecast period.